at Benzinga.com (Jan 14, 2015)
Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA...
Vivus (VVUS) shares are predictably chomping at the bit premarket, surging 13.3% after the FDA yesterday approved its weight-loss drug Qnexa/Qsymia. Shares had fallen sharply prior to the announcement. Also this morning, rivals Arena (ARNA) -5.9% and Orexigen Therapeutics (OREX) +3.2%.
From other sites
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Dec 30, 2014)
at Zacks.com (Dec 8, 2014)
at CNBC.com (Dec 2, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs